olpruva
Generic: sodium phenylbutyrate
olpruva: sourced relationships with 2 companies · 1 FDA decision.
olpruva evidence translation
What we can confirm
1 FDA record
What it means
More than one company relationship is source-backed. Until you choose one, AI stays drug-only and does not guess ownership.
What to watch
Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected
Prepared research question
What is verified about olpruva, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS)Urea Cycle Disorders
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Acer Therapeutics Inc. (ACER) Urea cycle disorders (UCDs) involving deficiencies of carbam… | Approved |
| ZEVRA THERAPEUTICS, INC. (ZVRA) Urea Cycle Disorders | Approved |
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with olpruva?
olpruva has dated SEC/FDA relationship records for Acer Therapeutics Inc., ZEVRA THERAPEUTICS, INC..
What is olpruva's latest FDA decision?
The most recent tracked FDA decision for olpruva is Approval, dated December 22, 2022.